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Abstract
Background: Infection with Chlamydia trachomatis (Ct) is the most commonly reported sexually transmitted
infection in Europe. In Germany, Ct screening is offered free of charge to pregnant women since 1995 and to
women < 25 years of age since 2008. For symptomatic individuals, testing is covered by statutory health insurance.
Study results have shown that repeat Ct infection occurs in 10–20% of previously infected women and men. Our
aim was to describe persons tested for Ct and to investigate the determinants of (repeat) Ct infection in women
and men in Germany.
Methods: We analysed Ct test results from men and women tested between 2008 and 2014 in laboratories
participating in the German Chlamydia trachomatis Laboratory Sentinel surveillance. Reinfection was defined as at
least 2 positive laboratory tests within more than 30 days. We performed logistic regression stratified by sex and, for
women, reason for testing to determine the effect of previous test results and age group on subsequent test
results.
Results: In total, 2,574,635 Ct tests could be attributed to 1,815,494 women and 123,033 men. 5% of women and
14% of men tested positive at least once. 15–19- and 20–24-year-old women tested positive at least once
respectively in 6.8 and 6.0%, while men respectively in 16.6 and 21.2%. Altogether, 23.1% of tested women and 11.9%
of tested men were tested repeatedly between 2008 and 2014. Among those who previously tested positive,
reinfection occurred in 2.0% of women and 6.6% of men. Likelihood to be tested Ct positive was higher in women and
men with a positive Ct test in the past compared to previously tested Ct negative, odds ratios 4.7 and 2.6 (p < 0.01)
respectively. Odds ratios ranged by age group and test reason.
Conclusion: A history of Ct infection increased the likelihood of infection with Ct in women and men taking into
account the result of the previous test. Health education, safer sex and treatment of partners are necessary for women
and men who have tested positive to prevent reinfection and complications and to interrupt the chain of transmission.
To identify potential reinfection repeat testing after treatment should be performed.
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Background
Infection with Chlamydia trachomatis (Ct) is the most
commonly reported sexually transmitted infection (STI)
in Europe [1]. According to data of the European Center
for Disease prevention and control (ECDC), young
people are particularly affected, with two-thirds (67%) of
the 384,555 reported cases in 2013 diagnosed amongst
15 to 24-year-olds [2]. This is however strongly influ-
enced by testing practices in reporting countries [2]. In
contrast to other STIs, Ct infection is very common in
the general population with prevalence ranging from 3.0
to 5.3% among women 18–26-years old and 2.4–7.3%
among men 18–26 years old [3]. Population-based esti-
mations for Germany showed prevalence of 4.4% for
sexually active 17-year-olds, 4.5% for 18- to 19-year-old
women and 4.9% for 25- to 29-year-old men [4]. Overall,
women aged 20 to 24 years are the group most frequently
diagnosed with Ct [5, 6]. The most consistent risk factors
associated with Ct infection in other studies are young age
and a high number of sexual partners [5, 7–9].
Ct causes infection in the lower genital tract. Un-
treated infected women may suffer from ascending in-
fection, which can lead to complications such as chronic
pain, inflammation and occlusion of the fallopian tubes,
which may result in infertility and ectopic pregnancy
[10, 11]. Ct increases the susceptibility and transmission
of HIV-infection [12]. The infection is asymptomatic in
up to 50% of women and 80% of men or may only display
mild symptoms. Therefore, Ct infection often remains
unnoticed and undiagnosed, and thus untreated [13].
Because of the considerable burden of Ct infection
and its sequelae, particularly in young women, many
countries have implemented Ct-related public health ac-
tivities to enhance detection and to prevent negative
consequences by treating infected individuals as soon as
possible. Approximately half of the European countries
offer opportunistic testing as a measure for Ct control.
Only a few countries have a systematic approach with
standard guidance for treatment and repeated testing
[14]; however, there are guidelines on the management
of Ct infection available for Europe [15]. Germany pub-
lished a guideline in 2016 to enable optimal diagnostics
and therapy of Ct [16]. In Germany, opportunistic
screening has been offered free of charge for statutory
insured pregnant women since 1995 and once annually
for statutory insured sexually active women under 25 years
of age since 2008. Currently, tests for men are refunded
by statutory health insurance if carried out for diagnostic
purposes, i.e. suspect infection based on symptoms or
anamnesis. There is no screening program for men in
Germany. There are no regulations for the contract
tracing in Germany and usually it is performed. With
the aim of gathering representative data on Ct tests, the
Robert Koch-Institute (RKI) established a voluntary
nationwide, laboratory-based Ct surveillance system, the
‘Ct laboratory sentinel’, in 2010 that accompanied the im-
plementation of the Ct screening programme for women
under 25 years old. Information on routine Ct-testing in
combination with test results, reason for testing and
patient-related information were collected from 24 micro-
biological laboratories in Germany offering Ct-diagnostics.
The Ct laboratory sentinel covers 34% of all Ct tests per-
formed in Germany. Study results based on the sentinel
data found an overall positive result rate of 3.9% amongst
women and 11.0% amongst men of all age groups [17].
Reinfection with Ct is possible and increases the likelihood
of complications and future acquisition and transmission
of the disease [18]. Based on international studies it was
estimated that 13.9% of women and 11.3% of men have
repeatedly been infected with Ct [19, 20] .
The association of previous infections, age and test
reason on reinfection have not yet been analysed yet in
Germany. The main aims of this study were to gather
evidence on whether current infection was more frequent
in women and men who had tested positive previously
compared to those who had tested negative previously
and, furthermore, to identify whether the age group and,
for women, the reason for testing, along with previous test
results, influences the result of a subsequent test. Our
findings will contribute to identify special risk groups for
Ct who are in need of health education and to generate
evidence for targeted Ct testing programmes.
Methods
The study population was composed of women and men
who were tested for Ct in Germany between January 1,
2008 and December 31, 2014 and whose assays were
tested in one of the laboratories participating in the Ct
Laboratory Sentinel that provided traceable patient-IDs
for a minimum of 3 years. The patient-IDs consisted of
an encrypted 32-digit hash code. If patients were tested
more than once within the same laboratory, data from
several samples could be assigned by this unique identi-
fier to one patient [16].
The following variables were used for analysis: patient-ID,
assay-ID, laboratory code, testing date, age, sex, test result
and test reason.
If information on sex or age was missing for some of
the assays with the same patient-ID, the missing values
were replaced by the information on sex and birth date
available from the other assays. If sex was missing in all
assays with the same patient-ID, these assays were
excluded from analysis.
Multiple assays with the same patient-ID that were
examined on the same day or within 7 consecutive days
were considered as only one test. In this case, the test
result was recorded as positive if at least one assay tested
positive and recorded as negative if all assays were
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negative. The decision to summarize multiple assays was
based on information regarding the time difference be-
tween the date when the sample was taken (available for
26% of all assays in the sample) and the date of testing.
Assays taken the same day by the physician were tested
within 7 days. Thus, multiple assays (such as vaginal and
rectal swabs) belonging to the same test-event might
have been tested in the laboratory on different days.
Assays with missing information on the test result
were excluded from analysis. Assays with missing infor-
mation on age group or reason for testing were kept in
the analysis.
The nucleic acid amplification test (NAAT) that is pre-
dominantly used in Germany for Ct testing is very sensi-
tive and can still be detected 3 weeks after therapy even
though the pathogen is no longer vital [21, 22]. Thus,
we included only those tests with a time interval of at
least 30 days from the preceding test in the analysis. Re-
infection was consequently defined as at least 2 positive
laboratory tests within a time interval of more than
30 days, following the definition of Brunham et al. [23]
and the European Guideline for the management of Ct
which recommends a test of cure 4 weeks after comple-
tion of therapy [15].
We described the number and proportions of per-
formed Ct tests, the number of tested persons and the
number of tests per person by sex, age group, reason for
testing and test result. Among repeat testers we calculated
median time between Ct tests by initial and subsequent
test result. “Initial test result” is defined as the first Ct test
that we have captured in the sentinel, however, this might
not be the first test of the individual.
We tested the association between the variables previ-
ous test result and age group and the outcome variable
test result by using logistic regression. Because of the
large sample size a p-value less than alpha = 0.01 was
considered significant in all calculations. We included
only tests from women and men at least 15 years old.
Separate models were calculated for men and women,
and for women, the analysis was additionally stratified
according to the reason for testing. The persons tested
only once in the surveillance period contribute to the
calculation of the proportion tested positive. To include
these persons into regression analysis, we defined the
variable previous test result as “unknown” as this group
is mixture of those previously never tested and those
tested positive or negative. The stratified univariable
analysis was compared to the results of a multivariable
logistic regression model. We tested improved goodness
of fit by using likelihood ratio tests (LRTs), and we calcu-
lated odds ratios (OR), probabilities (Pr), and the accord-
ing 99% confidence intervals. Including the interaction in
a model with two variables means that every combination
of age group and previous test result was estimated
separately. Since the result is a single odds it can directly
be transformed into a probability (P =O/(O + 1)). We
chose to present the probabilities, since for most people
this is the more familiar measure. This implied that the
probability of a positive test result had to be estimated
separately in all strata. The data were extracted from an
SQL dataset and analysed using STATA 14.
Results
Study population
General characteristics of Ct testing in Germany
During 2008–2014, 3,877,589 Ct tests were reported. Of
those, 2,574,635 tests were analysed, including 2,429,942
in women and 144,693 in men (Fig. 1). These tests could
be attributed to 1,815,494 women and 123,033 men. The
median age at the first Ct test was 26 years in women
(IQR: 22–32) and 33 years (IQR: 25–43) in men. Note
that this might not be the first test of the individual. In
women, most tests (45.0%) were performed because of
screening in pregnancy, followed by screening under
25 years (27.9%) and diagnostic testing (27.2%). The
median age at the time of the first positive test was
22 years for women (IQR: 19–25) and 28 years for men
(IQR: 23–36). Number of Ct tests and proportion of
positive Ct tests by reason of testing and age group
among women and men is given in Table 1.
Altogether, 23.1% (n = 420,220) of tested women and
11.9% (n = 14,680) of tested men were tested more than
once during the 7-year-surveillance period. Most of
those were tested twice (69.5% of women and 73.6% of
men). While 20.1 and 10.4% of women and 16.4 and
10.0% of men were tested 3 and 4 or more times,
respectively.
Amongst women and men tested more than once
13.6% (n = 57,133) and 34.6% (n = 5073) respectively had
at least one positive Ct test. In women and men, the me-
dian time until the date of the subsequent test was
shorter if the previous test was positive (Table 2).
Overall, in 0.5% (n = 8369) of women and in 0.8%
(n = 963) of men in all the tested men and women re-
infection was detected. Amongst repeatedly tested
women and men, reinfection was detected in 2.0 and
6.6%, respectively. The median time from the first to
the second positive test (reinfection) was 4.2 months
in women (IQR: 2.1–13.0) and 6.7 months in men
(IQR: 2.3–16.6).
Uni- and multivariable analysis
In the univariable logistic regression, the variables age
group and previous test result were significantly associated
with a positive result in a subsequent test (for detailed re-
sults of univariable analysis for women see Additional file
1: Table S1). A multivariable logistic regression model in-
cluding the variables age group and previous test result











attributable to 1,815,494 women
and 123,033 men
Assays from 8 laboratories where
assays were not traceable for at least 3 
years by patient-ID; N=1,179,052 
Assays with same patient-ID and
variation of sex and/or birthdate; 
N=3,418
Assays where information on sex was 
missing in all the assays with same 
patient-ID ; N=17,972
Assays with missing test results; 
N=12,923
Multiple assays with same patient-ID 
analyzed on 1 day; N=44,641
Multiple assays with same patient-ID 
analysed within 7 days were considered 
as same testing event ; N=8,130,  
Multiple tests with same patient-ID 
analyzed within 30 days were 
considered as confirmation tests 
belonging to previous testing event, 
N=36,818
Ct-tests included Ct-test excluded
Fig. 1 Flowchart of sample selection
Table 1 Number of Ct tests and proportion of positive Ct tests by reason of testing and age group among women and men,
2008–2014, n = 2,574,635
Women Men
Number (Proportion in %) Proportion Ct positive in % Number (Proportion in %) Proportion Ct positive in %
Tests
Total 2,429,942 (100) 4.0 144,693 (100) 12.4
Reason for testing (tests)
Screening under 25 years 571,054 (23.5) 5.0 n. a. n. a.
Screening in pregnancy 920,133 (37.9) 2.5 n. a. n. a.
Diagnostic testing 555,853 (22.9) 4.6 144,693 (100) 12.4
Unknown 382,902 (15.8) 5.1 n. a. n. a.
Age group (tests)
0–15 years 13,106 (0.5) 3.4 1048 (0.7) 3.0
15–19 years 342,892 (14.1) 6.8 6634 (4.6) 16.6
20–24 years 736,040 (30.3) 6.0 24,545 (17.0) 21.2
25–29 years 494,432 (20.4) 3.3 24,924 (17.2) 17.1
30–34 years 445,559 (18.3) 1.6 21,165 (14.6) 12.1
35–39 years 238,306 (9.8) 1.2 17,211 (11.9) 9.3
40+ years 157,824 (6.5) 1.3 46,868 (32.6) 5.7
Unknown 1783 (0.1) 5.1 2298 (1.6) 7.7
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showed that their interaction had a significant effect (Like-
lihood-Ratio-Test: p < 0.01). In regard to the probability of
a positive test result, a similar result was reported in
women for each test reason. Women and men of all age
groups who had previously tested positive showed a
higher probability of testing positive compared to their
peers who had previously tested negative. The estimated
probabilities for women and men are shown in Table 3 and
Figs. 2, 3 and 4. A different presentation of the results for
women and men in odds ratios can be found in Additional
file 2: Figure S1 and Additional file 3: Figure S2.
In women who were tested in the frame of screening
programmes (Table 3, Fig. 2), the probability to test
positive generally decreased with increasing age. The
proportion of previously positive pregnant women test-
ing positive again was highest amongst the 15–19 and
20–24-year-olds. However, the difference in regard to the
previous test result was most pronounced in pregnant
women in older age groups. Previously positive tested
women aged 35–39 years were 21.1 times and women
aged 40+ 20.5 times more likely to test positive compared
to their previously negative tested peers.
Amongst diagnostic tests the probability to test posi-
tive was highest in the age groups 15–19 and 20–24 years
in women who had previously tested positive. Overall,
the probability to test positive decreased with increasing
age, regardless of the previous test result. We observed a
slight increase in the probability of a positive test result
in the group of previously positive 35- to 39-year-olds.
The difference between women who had previously
tested positive and their previously negative tested
peers was most pronounced in the age groups 35–39
and 40+ years (OR: 7.1 and 5.4, respectively).
The probability to test positive in men (Table 3, Fig. 4)
was highest amongst 15–19 and 20- to 24-year-olds who
had previously tested positive. The probability to test posi-
tive decreased with increasing age; however, amongst men
who had previously tested positive, we observed a slight
increase in the age group 40+. The difference between
previously positive and previously negative tested men
was most distinct in the age groups 35–39 and 40+ years
(OR: 2.6 and 2.8, respectively).
Table 2 Median time interval until subsequent test in women and








Negative test 15.5 (IQR: 9.4–25.6) 7.4 (IQR: 3.1–15.2)
Positive test 3.0 (IQR: 1.7–8.9) 2.8 (IQR: 1.5–8.1).






Pr to test positive in % (99%-CI)
Women Men
Screening under 25 years Screening in pregnancy Diagnostic testing All tests
Negative 15–19 4.3 (4.1–4.6) 6.5 (6.0–8.1) 5.3 (4.8–5.8) 9.2 (5.9–14.1)
20–24 3.4 (3.2–3.5) 3.0 (2.9–3.4) 4.6 (4.3–4.9) 10.7 (9.0–12.6)
25–29 – 1.1 (1.0–1.3) 3.1 (2.9–3.4) 9.5 (8.0–11.2)
30–34 – 0.4 (0.4–0.5) 1.6 (1.4–1.9) 7.8 (6.5–9.3)
35–39 – 0.3 (0.2–0.4) 1.2 (1.0–1.5) 6.4 (5.2–7.9)
40+ – 0.3 (0.1–0.6) 1.1 (0.9–1.3) 5.5 (4.8–6.3)
Positive 15–19 12.6 (11.3–14.0) 28.4 (34.3–45.7) 16.8 (15.7–18.1) 18.6 (12.7–26.4)
20–24 9.8 (9.1–10.4) 18.5 (20.6–24.9) 12.7 (12.0–13.4) 19.2 (16.7–22.0)
25–29 – 10.4 (10.0–13.3 10.1 (9.2–11.0) 16.6 (14.3–19.3)
30–34 – 7.9 (6.8–10.8) 7.1 (6.0–8.4) 16.4 (13.8–19.5)
35–39 – 6.4 (4.3–10.7) 8.8 (6.9–11.0) 15.4 (12.3–19.1)
40+ – 5.9 (2.3–17.2) 5.9 (4.3–8.1) 16.9 (14.7–19.4)
Unknown 15–19 4.9 (4.7–5.0) 9.7 (10.2–11.3) 8.1 (7.7–8.4) 16.9 (15.7–18.2)
20–24 5.7 (5.6–5.8) 5.8 (6.0–6.4) 8.3 (8.0–8.6) 22.3 (21.6–23.1)
25–29 – 2.2 (2.1–2.3) 5.1 (5.0–5.3) 18.0 (17.3–18.7)
30–34 – 1.1 (1.0–1.1) 2.9 (2.7–3.0) 12.4 (11.8–13.1)
35–39 – 0.7 (0.6–0.8) 1.9 (1.8–2.1) 9.4 (8.8–10.1)
40+ – 0.6 (0.5–0.8) 1.6 (1.5–1.7) 6.1 (5.8–6.4)
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Discussion
To our best knowledge, this was the first German study
using a comparably large dataset of routine Ct tests to
examine the likelihood of infection while taking into
account the result of the previous test.
The likelihood of being diagnosed with Ct differed
based on the reason for testing and age in women. In
particular, young pregnant women who had a history of
Ct infection were at a high risk to test positive. As in
Germany the mean age of women at the time of the birth
of their first child was 29.3 years in 2015 [26], it is possible
that many pregnancies in the age group 15–19 years were
unwanted and screening for Ct has been carried out in the
context of an abortion and can be related to behaviour
with higher risk to acquire a STI as discussed before [17].
The proportion of positive tests was considerably
higher in men compared to women.
This can be explained by the fact that men are usually
tested because of symptoms or anamnestic reasons. Fur-























age group in years
Previously negative:Screening<25 Previously positive:Screening<25
Previously negative:Screening pregnancy Previously positive:Screening pregnancy
Fig. 2 Probability and 99%-CI of positive test results according to age group and previous test results in women tested in the frame of screening



















age group in years
Previously negative:Diagnostic testing Previously positive:Diagnostic testing
Fig. 3 Probability and 99% CI of positive test result according to age group and previous test results in women tested for diagnostic
reasons, 2008–2014
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that a substantial proportion of tested material is rectal
swabs [27] . Based on previous national and international
studies, it is known that the proportion of positive tests is
higher among MSM than heterosexual men [13, 29]. This
aspect might have influenced the data we observe.
Less than one fourth of all tested women and men
were tested repeatedly during the study period. Because
screening for women < 25 years of age should be per-
formed annually, and women can also be tested because
of screening in pregnancy and for diagnostic reasons, we
expected higher proportion of repeatedly tested women.
The small proportion of repeatedly tested women suggests
that screening programmes might not be sufficiently im-
plemented in Germany yet. To tackle insufficient coverage
of the existing screening programs, the Federal Agency for
Health Education (BZgA) designed an information cam-
paign and information materials on chlamydia screening
for physicians and attendees of medical praxes, in addition
to an ongoing poster campaign on STIs and correspond-
ing symptoms [28].
In all age groups and regardless of the reason for test-
ing, women and men with prior Ct infection had a high
probability to be tested positive for Ct (women: Pr:
5.9–28.4%, men: Pr: 15.4–19.2%). The probability of re-
infection varied substantially among women by age and
test reason with highest probabilities in young women,
especially if tested within screening in pregnancy. Stud-
ies have shown that early first intercourse was associ-
ated with subsequent sexual risk behavior [9, 24] which
also leads to a higher probability of acquiring an STI.
We observed less age-related variation for reinfection
among men, though younger men had a higher prob-
ability for reinfection. We believe that this might be
related to a mixed population of men in our data set.
The group that repeatedly tested positive might be
more at risk of infection, for example HIV positive
MSM. Bacterial STI are more common in HIV positive
MSM [13, 30]. However, we lack data in current study
to analyse this in more detail. Additionally, the detection
rate of STI, especially asymptomatic infections, among
men frequently accessing testing might be higher.
Currently, evidence remains insufficient to recommend
routine Ct-screening for all sexually active young men in
Germany, partially because men rarely develop sequelae
[31]. Nonetheless, the benefit of a screening programme for
high-risk populations of men has been supported, for
example Gift et al. found that Ct-screening programme
targeting high-risk men was cost-saving compared to
programme expanding screening of lower-risk women [32].
Interestingly, previously positive tested women and
men in the older age groups showed the highest odds ra-
tios to test positive; women especially when screened in
pregnancy. This finding could indicate that these women
and men aged 30 years and older with repeat infection,
may represent a small group with ongoing sexual risk
behavior that is thus more likely to contract repeat infec-
tion than their previously negative tested peers. Neverthe-
less, the absolute risk differences (in percent points)
between previously positive and previously negative tested
women and men by age group are much higher in the
young age groups. The increased probability of infection
for women and men with a history of Ct infection has been
found by several other studies. In a study population of
adolescent girls, Batteiger et al. found that incident Ct
infections occurred in 78.1% of participants with infections
at baseline compared to 51.7% of participants without in-
fection at baseline [33]. The results of Dunne et al. showed



















age group in years
Previously negative Previously positive
Fig. 4 Probability and 99% CI of positive test result according to age group and previous test results in men, 2008–2014
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men screened for Ct infection [34], whereas Rietmejer et
al. found a 2.4-fold increased risk of reinfection for women
and men with Ct infection at baseline amongst female and
male patients of an STI clinic [25]. However, because of
wide variations amongst the definitions of reinfection, the
study designs and the composition of study populations, it
is difficult to compare these numbers directly to our
results.
Untreated infections of current partners and unpro-
tected sex with new partners contribute to repeated in-
fections [17, 35]. Although treatment with antibiotics is
highly effective [33], a small proportion of alleged reinfec-
tion might be ongoing infections after treatment failure or
insufficient adherence to treatment. Several studies have
shown that persons with prior Ct infection were at a high
risk of reinfection [9, 20, 25, 33, 34]. However, a link
between previously diagnosed and treated Ct infections
and the development of immunity against Ct has also
been discussed [23].
The testing interval was considerably shorter if a previ-
ous Ct test was positive. A median time to repeat testing
after a positive test result of approximately 3 months
might indicate compliance to European guideline that rec-
ommends repeat testing in women and men < 25 years of
age within 3 to 6 months after a positive Ct test result
[15]. Additionally, test of cure is recommended for preg-
nant women, if symptoms persist, if non-compliance is
suspected or if second- and third-line treatments have
been used [15]. However, the median time to the reinfec-
tion depends largely on the testing patterns and cannot
directly be related to the natural history of infection.
The relatively small proportion of persons with re-
infection we found in our whole sample was likely a
consequence of the small proportion of repeatedly tested
persons in our sample. While among those tested
repeatedly during the study period, the reinfection was
observed in 2% of women and 6.5% of men. The median
time to reinfection was 4.2 month in women and
6.7 months in men. Similar to our results, studies from the
United States and Australia have found a median time to
reinfection of 5.2 months amongst 19-year-old women [29]
and of 4.6 months amongst women aged 16 to 25 years
[9]. The treatment failure can still be observed 7–8 weeks
after antibiotic treatment. Therefore, it is important to be
able to distinguishing between actual reinfection with Ct
and treatment failure [36]. As we have no information on
treatment and detailed follow up data, we cannot distin-
guish between treatment failure and reinfection. Therefore,
our approach to define a reinfection as each infection that
occurs after a 30 days period is sensitive and potentially
misclassifies those with treatment failure. In a sensitivity
analysis, where we defined a reinfection as a subsequent
positive test occurring after 42 days, we observed a reinfec-
tion in 1.9% (instead of 2.0%) of repeatedly tested women
and in 6.4% (instead of 6.6%) of repeatedly tested men.
With this approach, it is probable that some of the true
reinfections are misclassified treatment failures.
Limitations
First, because several samples of a person only received
the same patient-ID if tested in the same laboratory, the
true number and proportion of reinfection in the study
population may have been underestimated. If samples of
one person were sent to different laboratories, e.g., be-
cause someone changed physician or the physician chan-
ged the diagnosing laboratory, these persons were either
lost to follow-up or their tests were sampled in the Ct
laboratory sentinel again, but with a new patient-ID. How-
ever, we expect that the proportion of previously tested
persons having received a new patient-ID represents only
a small fraction of the analysed tests.
Another limitation is that the Ct laboratory sentinel
dataset offers no information on whether a person who
tested positive received therapy and whether the treat-
ment was successful. Thus, ongoing Ct-infections due to
non-compliance or treatment failure could have been
falsely classified as reinfection in this study. Further-
more, there is no information on behavioural factors that
may influence the likelihood to be tested positive.
Finally, the Ct Laboratory Sentinel data might lack
representativeness for the target population in Germany,
even though the sentinel generally reached a good cover-
age in the period 2008–2014 and it was possible to
collect a large number of samples representing one third
of all performed Ct tests in Germany [17]. Still, the par-
ticipation of laboratories was voluntary and it is unclear
whether participating laboratories differed systematically
from the non-participating laboratories, e. g. in terms of
tested population. Data from the laboratories with con-
tinuous follow-up for at least 3 years used in current
analysis did not substantially differ from rest of the par-
ticipating laboratories regarding distribution of sex, age
and proportion tested positive.
Conclusions
We describe how history of Ct infection increased the
likelihood of infection with Ct in women and men, tak-
ing into account age and reason for testing (in women).
This helps to identify groups in need of health education
and generates evidence for a more targeted testing
strategy.
The high proportion of positive tests and of reinfection
found amongst men supports risk-based screening of
sexually active young men. However, future studies must
determine all potential risk factors and identify the
categories of transmission in men to identify for which
group Ct screening is most beneficial.
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We recommend that women and men who have been
diagnosed positive with Ct should be consulted on pre-
vention, symptoms and possible consequences of Ct
infection to avoid reinfection.
To identify potential reinfection – and persisting infec-
tion – repeat testing after treatment should be performed.
To increase the number of those getting tested, preventive
measures for young women and men like awareness cam-
paigns on Ct infection and testing opportunities as well as
sex education in schools should be implemented. Till
now, preventional campaigns for Ct in Germany do not
address a higher risk for infection of persons who were
tested positive before specifically. On basis of our data, we
recommend to adjust the respective materials to
emphasize this. Awareness about Ct infection, increased
risk of reinfection for person tested Ct positive before, and
adaequate screening should also be raised amongst physi-
cians and gynaecologists to enhance the coverage of the
screening programmes. Further studies are necessary to
examine whether these measures show the desired effect.
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